Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study

References

• The French Cooperative Group on chronic lymphocytic leukemia (1990) "Effects of chlorambucil and the therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 Patients", Blood, 75, 1414–1421.
   Google Scholar
• Balfour, J.A. and Goa, K.L. (2001) "Bendamustine", Drugs, 61(5), 631 — 640.
   Web of Science ®Google Scholar
• Ozegowski, W. and Krebs, D. (1971) "IMET 3393, gamma-(1-Methyl-5-bis-(B-chlordthyl)-amino-benzimidazoly1(2))-buttersäure-hydrochlorid, em n neues Zytostatikum aus der Reihe der Benzimi-dazol-Loste", Zbl. Pharm., 110, 1013–1019.
   Google Scholar
• Anger, G., Hesse, P., Ki5hler, P. and Baufeld, H. (1967) "Erste klinische Erfahrungen mit einem neuen Zytostatikum", Deutsch. Gesundheitswes., 22, 1079 — 1084.
   PubMedGoogle Scholar
• Ruffert, K., Jahn, H., Syrbe, G., et al. (1989) "Cytostasan (Bendamustin) in der Alternativtherapie maligner Non-Hodgkin-Lymphome", Z. Klin. Med., 44, 671 —674.
   Google Scholar
• Anger, G., Fink, R., Fleischer, J., et al. (1975) "Vergleichsuntersu-chungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogra-nulomatose und dem Bronchialkarzinom", Deutsch. Gesund-heitswes., 30, 1280–1285.
   Google Scholar
• Bremer, K. and Roth, W. (1996) "Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas", Tumordiagn. u. Ther., 17, 1— 6.
   Web of Science ®Google Scholar
• McLaughlin, P., Hagemeister, F.B., Romaguera, J.E., et al. (1996) "Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma", J. Clin. Oncol., 14, 1262–1268.
   Web of Science ®Google Scholar
• McLaughlin, P., Cabanillas, F., Grillo-Lopez, A.J., et al. (1996) "IDEC-C2B8 anti-CD20 antibody final report on a phase II pivotal trial in patients with relapsed low grade or follicular Lymphoma", Blood, 88, 90a, Suppl 1.
   Google Scholar
• Weide, R., Heymanns, J., Gores, A. and Köppler, H. (2002) "Bendamustine Mitoxantrone and Rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas", Leukemia and Lymphoma, 43(2), 327–331.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Horning, Si., Coiffier, B., et al. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma", J. Clin. Oncol., 17, 1244–1253.
   Web of Science ®Google Scholar
• Cheson, B.D., Bennett, J.M., Rai, K.J., et al. (1988) "Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Re-commendations of the NCI-Sponsored Working Group", Am. J. Hematol., 29, 152–163.
   PubMed Web of Science ®Google Scholar
• Jaffe, ES., Harris, N.L., Stein, H. and Vardiman, J.W. (2001) (Eds): WHO—Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. IARC Press: Lyon.
   Google Scholar
• Kay, N.E., Hamblin, Ti., Jelinek, D.F., et al. (2002) "Chronic lymphocytic leukemia", Hematology, Am. Soc. Hematol. Educ. Program, Pp 193–213.
   Google Scholar
• Damle, RN., Wasil, T., Fais, F., et al. (1999) "Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia", Blood, 94, 1840–1847
   Web of Science ®Google Scholar
• Keating, Mi., Flinn, I., Jain, V., et al. (2002) "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludar-abine: results of a large international study", Blood, 99(10), 3554 — 3561.
   PubMed Web of Science ®Google Scholar
• Dreger, P., Michallet, M. and Schmitz, N. (2000) "Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective", Ann. Oncol., 11(Suppl 1), 49–53.
   Google Scholar
• Dreger, P. and Montserrat, E. (2002) "Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia", Leukemia, 16(6), 985–992.
   PubMed Web of Science ®Google Scholar
• Keating, Mi., Chiorazzi, N., Messmer, B., et al. (2003) "Biology and treatment of chronic lymphocytic leukemia", Hematology, Am. Soc. Hematol. Educ. Program, Pp 153–175.
   Google Scholar
• Leoni, L.M., Bailey, B., Reifert, J., et al. (2003) "SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action", Blood, 102, abstract 2363.
   Google Scholar
• Bremer, K. (2002) "High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low grade non-Hodgkin's lymphomas", J. Cancer Res. Clin. Oncol., 128(11), 603 — 609.
   Web of Science ®Google Scholar
• Czuczman, M.S., Grillo-Lopez, A.J., White, CA., et al. (1999) "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", J. Clin. Oncol., 17, 268–276.
   PubMed Web of Science ®Google Scholar
• Hiddemann, W., Dreyling, M.H., Forstpointer, R., et al. (2003) "Combined Immuno-Chemotherapy (R-CHOP) significantly im-proves time to treatment failure in first line therapy of follicular lymphoma — Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)", Blood, 102, abstract 352.
   Google Scholar
• Marcus, R., Imrie, K., Belch, A., et al. (2003) "An International multi-centre, randomized, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma", Blood, 102, abstract 87.
   Google Scholar
• Dreyling, M.H., Forstpointer, R., Repp, R., et al. (2003) "Combined Immuno-Chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma — Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)", Blood, 102, abstract 351
   Google Scholar
• Rummel, M., Kim, S.Z., Chow, KU., et al. (2003) "Bendamustine and Rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas", Blood, 102, abstract 353.
   Google Scholar